2010/12/12

Afobazol

Release form, composition and packing

Of white or white with a touch of color Valium, Valium, with a facet.

1 tab. морфолиноэтилтиоэтоксибензимидазола dihydrochloride 5 mg-10 mg.

Excipients: potato starch, microcrystalline cellulose, lactose, povidone, magnesium stearate. Clinico-pharmacological group: Tranquilizer (anxiolytic).

Pharmacological action

Afobazol - a 2-merkaptobenzimidazola, a selective anxiolytic, not related to the class of benzodiazepine receptor agonists. Prevents the development of membranozavisimyh changes in GABA-receptor. The drug has anxiolytic effect of activating components that are not accompanied by gipnosedativnymi effects (sedation is detected at doses of 40-50 times the ED50 for the anxiolytic action). Do not miorelaksantnoe drug properties, negative impact on memory and attention.

Using drugs is not formed by drug dependence and withdrawal syndrome develops.

Effect of the drug sold mainly in the form of a combination of anxiolytic (protivotrevozhnogo) and easily enabling (activating) effects. Reducing or eliminating anxiety (concern, a bad feeling, fear, anger), stress (fearfulness, tearfulness, anxiety, inability to relax, insomnia, fear), and, hence, somatic (muscular, sensory, cardiovascular, respiratory, gastrointestinal intestinal symptoms), autonomic (dry mouth, sweating, dizziness), cognitive (difficulty concentrating, impaired memory) violations observed at 5-7 days of treatment Afobazol.

The maximum effect is achieved by the end of 4 weeks of treatment and stored in posleterapevticheskom period, an average of 1-2 weeks. Especially shows the use of the drug in patients with predominantly asthenic personality traits as alarming suspiciousness, insecurity, increased vulnerability and emotional lability, tendency to emotional stress reactions. Afobazol non-toxic (LD50 in rats is 1.1 g with ED50 of 1 mg).

Pharmacokinetics

Suction

Cmax was 0.13 ± 0.073 mg / ml.

Distribution

The average retention time of the drug in the body - 1.6 ± 0.86 hours intensively distributed in well-vascularised organs.

Breeding

T1 / 2 at 0.82 pm

Statement

Afobazol used in adults with anxiety disorders:
generalized anxiety disorder, neurosis, adjustment disorder;
patients with various somatic (bronchial asthma, irritable bowel syndrome, ACS, coronary artery disease, arrhythmia, hypertension), dermatological and oncological diseases;
sleep disturbances associated with anxiety;
neurocirculatory asthenia;
syndrome, premenstrual tension;
Alcohol withdrawal syndrome;
to ease withdrawal symptoms during smoking cessation.

Dosing regimen

Drug is prescribed inside, after a meal. Single dose of 10 mg daily dose - 30 mg, divided into 3 doses throughout the day. The duration of the exchange rate of the drug is 2-4 weeks. If necessary, the daily dose may be increased to 60 mg and the duration of treatment to 3 months.

Side effect

Possible: an allergic reaction, hypersensitivity to the drug.

Contraindications
pregnancy;
Lactation (breastfeeding);
childhood and adolescence to 18 years;
hypersensitivity to the drug.

Pregnancy and lactation

The drug is contraindicated during pregnancy and lactation (breastfeeding).

Overdose

Symptoms: When a large overdose and intoxication may develop sedation and increased sleepiness without manifestations miorelaxation.

Treatment: As an emergency appoint n / a caffeine-sodium benzoate 20% solution of 1 ml 2-3 times / day.

Drug Interactions

While the application Afobazol no effect on the action of ethanol and thiopental.

While the application Afobazol potentiates anticonvulsive effect of carbamazepine.

While the application Afobazol causes increased anxiolytic action of diazepam.

Conditions and terms of

The drug should be kept away from children, dry, dark place at temperatures not above 25 ° C. Shelf life - 2 years.